Key Points
- Insider selling: Peter Rahmer sold 11,684 shares at $7.62 on Jan. 27 (and another 1,354 shares on Jan. 28), trimming his stake by about 4%, while CFO Thomas Catinazzo and Donald Bergstrom also executed sizable sales across Jan. 27–28.
- Although the clustered insider sales may weigh on near‑term sentiment, insiders still retain large positions and institutional ownership is high at 96.98%, reducing the likelihood of a strategic control shift.
- Shares trade around $7.7 with a market cap of $1.34B and recent negative EPS (missed last quarter); analysts' consensus is Moderate Buy with a $16.57 price target.
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 1,354 shares of the company's stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $8.45, for a total transaction of $11,441.30. Following the transaction, the insider owned 276,610 shares in the company, valued at approximately $2,337,354.50. This trade represents a 0.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Peter Rahmer also recently made the following trade(s):
- On Tuesday, January 27th, Peter Rahmer sold 11,684 shares of Relay Therapeutics stock. The stock was sold at an average price of $7.62, for a total transaction of $89,032.08.
Relay Therapeutics Trading Up 0.8%
NASDAQ:RLAY opened at $7.71 on Friday. Relay Therapeutics, Inc. has a twelve month low of $1.77 and a twelve month high of $9.04. The company has a market cap of $1.34 billion, a PE ratio of -4.41 and a beta of 1.55. The company's 50 day moving average is $7.96 and its two-hundred day moving average is $5.95.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). As a group, analysts expect that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.
Institutional Investors Weigh In On Relay Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Relay Therapeutics by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company's stock valued at $71,000 after purchasing an additional 1,757 shares during the period. FNY Investment Advisers LLC increased its holdings in Relay Therapeutics by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock valued at $34,000 after buying an additional 5,000 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in shares of Relay Therapeutics in the second quarter worth about $35,000. May Hill Capital LLC purchased a new stake in shares of Relay Therapeutics during the 2nd quarter worth about $38,000. Finally, Focus Partners Advisor Solutions LLC acquired a new stake in shares of Relay Therapeutics during the 2nd quarter valued at about $39,000. Institutional investors and hedge funds own 96.98% of the company's stock.
Relay Therapeutics News Summary
Here are the key news stories impacting Relay Therapeutics this week:
- Positive Sentiment: Shares are trading up intraday, sitting above the 200‑day moving average—a technical signal some investors view as constructive. MarketBeat RLAY quote
- Neutral Sentiment: Despite the recent sales, insiders still hold large positions (many hundreds of thousands of shares), which reduces the likelihood of a meaningful shift in strategic control; the disclosures show percentage ownership declines but substantial remaining stakes. (See SEC filings linked below.)
- Negative Sentiment: CFO Thomas Catinazzo sold 1,695 shares at an average $8.45 on Jan. 28 (total ~$14.3k), and had also sold 13,820 shares at ~$7.62 on Jan. 27; these filings show a multi-day reduction in the CFO’s ownership. Catinazzo filings
- Negative Sentiment: Insider Peter Rahmer sold 1,354 shares at $8.45 (Jan. 28) and 11,684 shares at $7.62 (Jan. 27), reducing his stake by several percent—more insider selling that can weigh on sentiment. Rahmer filings
- Negative Sentiment: Insider Donald A. Bergstrom sold 2,686 shares at $8.45 and 18,895 shares at $7.62 across Jan. 27–28, cutting his position by ~4%. Large, clustered insider sales can amplify near‑term downward pressure. Bergstrom filings
- Negative Sentiment: Market commentary highlights recent weakness in RLAY (example: a note explaining a ~5.2% drop), which may reflect short‑term sentiment, sector dynamics, or news-driven selling; that coverage can push momentum lower even if fundamentals are unchanged. Why RLAY is down 5.18%
Analyst Upgrades and Downgrades
A number of research firms recently commented on RLAY. Oppenheimer raised Relay Therapeutics from a "market perform" rating to an "outperform" rating and set a $14.00 target price for the company in a report on Monday. Wells Fargo & Company upgraded shares of Relay Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $6.00 to $13.00 in a research note on Friday, December 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Relay Therapeutics in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.57.
View Our Latest Stock Analysis on Relay Therapeutics
About Relay Therapeutics
(
Get Free Report)
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
